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Abstract: Problem statement: Splenectomy is accompanied by a lifelong risk of overwhelming post 
splenectomy infection, mainly caused by encapsulated bacteria such as Streptococcus pneumoniae. 
The mortality rate in those infected patients remains high. Therefore the pneumococcal polysaccharide 
vaccine  has  been  recommended.  Approach:  To  obtain  information  on  the  immunity  levels  of 
pneumococcal  antibody,  in  splenectomized  β-thalassemia  patients  in  south  of  Iran.  Patients  and 
methods:  This  descriptive  and  cross  sectional  study  was  carried  out  on  263  splenectomized  β-
thalassemia patients in south of Iran, June 2007-September 2008. Anti-pneumococcal vaccine antibody 
concentrations were measured by the enzyme-linked immunosorbent assay method. The patients were 
divided into two groups based on antibody concentrations: Group 1: Hyporesponsiveness patients or 
non-immune with less than 250 mU mL
-1 antibody concentrations and group 2: Immune patients or 
responder with equal or more than 250 mU mL
-1 antibody concentrations. Results: The results showed 
that 33.80 and 66.20% of the patients were immune and non-immune to pneumococcal infections, 
respectively.  There  was  an  inverse  significant  between  Immunity  level  with  the  period  after 
pneumococcal vaccination (r = -0.683, p = 0.0001). Conclusion: These results suggest that a high 
percentage splenectomized β-thalassemia patients are poor responders to pneumococcal vaccination. 
Therefore evaluations immunity levels of pneumococcal vaccine and re-vaccination for pneumococcus 
are recommended in these patients. 
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INTRODUCTION 
 
  The  term  thalassemia  (derived  from  the  Greek 
“Thalassa”,  which  means  “the  sea”  stating  to  the 
Mediterranean-and “emia”, meaning “related to blood”) 
designates  a  diverse  group  of  genetic  disorders  of 
hemoglobin synthesis characterized by a disturbance of 
the  making  of  globin  chains,  leading  to  anemia, 
ineffectual  erythropoiesis  (Weatherall  and  Clegg, 
2001), particularly in some parts of the world like the 
Mediterranean area, north and west of Africa and the 
Middle  East.  Its'  worldwide  incidence  is  about  2  per 
1,000 newborns while its' prevalence in Iran is 8-4 per 
1,000 newborns and frequency of thalassemia gene in 
Iran is 4-10% (Ali et al., 2008). 
  Health  wealth  is  insufficient  in  most  of  the 
countries where the disease is common (Karnon et al., 
1999). In most of the countries where β-thalassemia is 
common,  there  is  not  a  realistic  situation  for  these 
patients. The blood transfusion resource  was basic at 
best and desferrioxamine supply was inconsistent. Full 
facial  and  clinical  features  of  the  disease  from  the 
ineffective bone marrow expansion were presented in 
most of the patients. Splenomegaly was seen in patients 
early  in  their  lives  and  splenectomy  was  done  at  a 
relatively  young  age.  Splenectomy  is  necessary  in  β-
thalassemia  patients  when  the  spleen  develops 
hyperactive,  leading  to  extreme  destruction  of 
erythrocytes  and  thus  growing  the  need  for  regular 
blood transfusions, which in turn outcomes more iron Am. J. Immunol., 8 (2): 33-37, 2012 
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accumulation.  As  a  result,  splenectomy  is  commonly 
done  (Hoe  et  al.,  1994).  Infectious  diseases  are  the 
second  most  common  cause  of  mortality  and  a  main 
cause of morbidity in β-thalassemia patients (Cadili and 
Gara, 2008). Some immunological disorders have been 
reported in β-thalassemia patients (Gharagozloo et al., 
2009)  and  asplenia  is  one  of  the  essential  causes  of 
immunodeficiency  in  patients  with  β-thalassemia 
(Ricerca et al., 2009).  
  As the spleen is more effective at eliminating non-
opsonized  bacteria,  mostly  encapsulated  organisms, 
asplenia  can  lead  to  immune  defects  to  encapsulated 
micro-organisms  (Cadili  and  Gara,  2008)  and 
splenectomized β-thalassemia patients are more at risk 
of  developing  sepsis  by  these  encapsulated  bacteria. 
Overwhelming Postsplenectomy Infection (OPSI) is a 
serious complication of asplenia and is usually caused 
by encapsulated bacteria (Waghorn, 2001). Over 70% 
of  all  cases  of  OPSI  are  due  to  Streptococcus 
pneumoniae,  even  though  no  more  than  5%  of  other 
septic episodes are attributable to this bacterium (Cadili 
and  Gara,  2008).  To  prevent  OPSI,  a  pneumococcal 
vaccine with purified capsular polysaccharide from the 
pneumococcal types that commonly cause infection has 
been recommended (Austrian, 1977). 
  Iran  splenectomized  β-thalassemia  patients  are 
vaccinated with Pneumococcal vaccine (Pneumovax) to 
prevent OPSI 14 days before splenectomy.  
  Unfortunately, none of the Iranian splenectomized 
β-thalassemia patients have been assessed for immunity 
level  to  Streptococcus  pneumonia  and  there  is  no 
monitoring for this immunity in these patients in IRAN. 
This  was  the  first  study  to  determine  the  antibody 
response to vaccination for Streptococcus pneumoniae 
with  Pneumococcal  vaccine  (Pneumovax)  in  Iranian 
splenectomized β-thalassemia patients. 
 
METERIALS AND METHODS 
 
Patients and methods:  
Patients:  A  total  of  263  β-thalassemia  patients  who 
underwent  splenectomy  and  vaccinated  with 
Pneumovax, who were referred to thalassemia centers 
of in the south of Iran, were enrolled to this descriptive 
and cross sectional study.  
  Exclusion criteria for all the patients included: Any 
immune suppressive therapy in the prior six months and 
a  history  of  immunodeficiency  and  Acquired 
Immunodeficiency Syndrome (AIDS). This study was 
carried out from June 2007 to September 2008.  
  The study protocol was reviewed and approved by 
the Research Ethics Committee of Jahrom University of 
Medical Sciences and informed consent was obtained 
from each patient. 
Methods:  A  questionnaire  was  designed  to  collect 
demographic  information  and  medical  history  of  the 
patients by reviewing the patient’s records. All patients 
vaccinated intramuscularly with a single dose of 0.5 ml 
of  Pneumovax  14  days  before  splenectomy.  Blood 
samples  were  taken  from  the  patients  and  serum 
samples were stored at -70°C until assayed for antibody 
measurements.  Specific  antibodies  against 
Pneumococcal  Capsular  Polysaccharide  (PCP)  were 
measured  using  the  protocol  of  the  third-generation 
enzyme-linked immunosorbent assay format (Wernette 
et al., 2003; Mahmoodi et al., 2009).  
  The assay has been designed to measure the IgG 
antibody  responses  to  pneumococcal  vaccine 
incorporating  23  polysaccharides  isolated  from 
Streptococcus  pneumoniae.  These  polysaccharides 
correspond  to  approximately  80%  of  the  commonly 
encountered,  virulent  serotypes.  The  levels  of  serum 
specific anti-PCP IgG antibodies  were determined by 
an  enzyme  immunoassay  kit  (Pneumococcus  IgG 
Immonupotency  level/E-DG-MZ-001/04-04,  ZenTech, 
Belgium).  In  this  assay,  microwaves  were  pre-coated 
with  the  PCP  antigen.  Serum  samples  were  tested  in 
accordance with the manufacturer’s instructions. Serum 
samples were diluted 1:510. The titers of anti PCP IgG 
antibodies  were  determined  with  reference  to  the 
standard serum included in the kit and were expressed as 
mili  unit/ml  (mu/ml).  Some reference  plasmas  with 
assigned values of anti PCP IgG were used as Calibrators 
to draw standard curve. The sensitivity of this kit was 6.9 
mU/mL. Serum samples were tested in duplicate.  
  Corresponding anti PCP IgG antibodies in mu/ml 
are  obtained  by  interpolating  the  observance  of  each 
sample on the calibration curve. According to directions 
on this kit the result Interpretation was done as follows: 
  
·  Lower than 250 mU mL
-1 = Deficient in anti PCP 
IgG antibodies or hyporesponsiveness 
·  Equal  to  or  more  than  250  mU  mL
-1  =  good 
response or Immune to pneumococcal infection 
·  All  patients  were  categorized  according  to  their 
serum anti-pneumococcal IgG titers 
 
Statistical analysis: Data were analyzed using an SPSS 
14.0  software  package.  Specific  antibody  titers  were 
expressed as the geometric mean. T test and correlation 
test were performed for analysis.  
 
RESULTS 
 
  A  total  of  263  splenectomised  β-thalassemia 
patients, (133 males and 130 females), aged 18-64 years 
(mean, 41±13 years) and with time post pneumococcal 
vaccination  12-336  mounts  (mean,  106.77±67.62) 
mounts were evaluated for antibody response to PPV23.  Am. J. Immunol., 8 (2): 33-37, 2012 
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Table 1: Demographic  and  serum  anti-pneumococcal  IgG  titers  for 
the patients   
    Time post  Anti- 
    vaccination  pneumococcus 
Sex  Age (years)  (mounts)  IgG (mU/ml) 
Female N=130 (49.40%)  18.39±4.55  94.85±59.00  212.67±68.72 
Male N=133 (50.60%)  19.25±6.40  118.42±73.46  199.00±74.50 
P-value  0.214  0.004  0.123 
 
Table-2: Comparison of Hypo-responsive group Vs responder group 
    Time after  Anti- 
    vaccination  pneumococcus 
Groups  Age (years)   (mounts)  IgG (mU/mL) 
Hypo-responsive  19. 17±5.00  133.88±60.71  167.30±52.15 
Responder  18. 16±6.53  53.76±45.52  280.94±37.42 
P-Value  0. 165  0.0001*  0.0001* 
There  were  found  inverse  significant  correlations  between  anti-
pneumococcal IgG titers and time post vaccination (r = -0.683, p = 
0.0001) 
 
Demographic and serum anti-pneumococcal IgG titers 
(mU/mL) for all patients were summarized in Table 1. 
All patients were categorized according to their serum 
anti-pneumococcal IgG titers (mU/mL) to two groups: 
 
·  Group-1  (hyporesponsive):  174  patients  (66.2%) 
with  mean  167.30±52.15  mU/mL  serum  anti-
pneumococcal IgG 
·  Group-2  (immune  or  responder):  89  patients 
(33.8%) with mean 280.30±52.15 mU mL
-1 serum 
anti-pneumococcal IgG 
 
  There were significant differences between serum 
anti-pneumococcal IgG titers and time post vaccination 
in two groups. The characteristics of two patient groups 
(hypo-responsiveness  Vs  immune  or  responder) 
according to anti-pneumococcal IgG titers are presented 
in Table 2.  
 
DISCUSSION 
 
  Splenectomized β-thalassemia patients have a high 
risk  of  Streptococcus  pneumoniae  infections,  which 
could  be  due  to  the  reduced  antibody  response  to 
bacterial polysaccharide antigens in these patients due 
to splenectomy (Zarina et al., 2010).  
  Although  pneumococcal  immunization  in 
Splenectomized β-thalassemia patients is recommended 
(Sheikha et al., 2007), there are few reported studies 
involving  the  evaluation  of  the  antibody  response  to 
polysaccharide antigens in these patients or the efficacy 
of pneumococcal vaccination in these patients (Sakran 
et al., 2010).  
  Sufficient  antibody  response  to  pneumococcal 
antigens  (equal  to  or  more  than  250  mU  mL
-1)  in 
Splenectomized β-thalassemia patients can show the 
significance of vaccination in order to protect them 
against  pneumococcal  infections  (Cadili  and  Gara, 
2008; Waghorn, 2001; Austrian, 1977).  
  The result of the present study indicated that 66.2% 
of  Splenectomized  β-thalassemia  patients  were  hypo-
responsive  to  pneumococcal  antigens,  which  is  in 
arrangement  with  the  study  performed  by  Rao  et  al. 
(1995)  showing  that  42%  of  the  vaccinated 
Splenectomized β-thalassemia patients were protective 
to  Streptococcus  pneumonia.  This  indicates  that 
measurement of post-vaccination antibody levels can be 
used to identify the poor responders who most likely 
are at increased risk of pneumococcal infection. 
  In the present study, mean anti-pneumococcal IgG 
titers  in  male  patients  did  not  differ  from  female 
patients. This data shows that anti-pneumococcal IgG 
titer is independent of sex in these patients.  
  However,  poor  responders  proved  to  be 
unresponsive  to  booster  doses  of  polysaccharide 
antigens (Rodriguez-Barradas et al., 1996; Petrasch et 
al., 1997). Purified polysaccharide antigens result in T 
cell-independent, type-2 antibody formation and do not 
elicit  memory  B  cells.  T  cell-independent  antibody 
responses  cannot  be  boosted  to  produce  secondary 
responses.  It  is  possible  that  conjugate  vaccines 
(capsular  polysaccharides  conjugated  to  carrier 
proteins) might improve the immune response in non-
responders  to  PPV:  the  7-valent  pneumococcal 
conjugate  vaccine  has  improved  the  response  rate  to 
PPV23  in  patients  with  selective  antibody  deficiency 
(Zielen et al., 2000). 
  The  results  obtained  here  suggest  that  an 
immunization  policy  with  pneumococcal 
polysaccharides might help to protect the majority of 
Splenectomized β-thalassemia patients against invasive 
pneumococcal diseases; therefore, we suggest that the 
vaccine  be  administered.  Nevertheless,  some  subjects 
who  cannot  mount  an  adequate  antibody  response  to 
polysasaccharide antigens will remain at significant risk 
for  such  infections  and  should  be  offered  other, 
prophylactic  methods  such  as  immunization  with 
pneumococcal conjugate vaccines. 
   According  to  an  inverse  significant  correlation 
between mean anti-pneumococcal IgG titers and time 
post  splenectomy  which  was  found  from  this  study, 
indicates a decline of anti-pneumococcal IgG titer along 
the  time.  Published  data  indicate  that  vaccinated 
immunocompromised  patients,  who  had  a  nearly 
normal antibody response to pneumococcal vaccine and 
immune  patients  to  Streptococcus  pneumonia,  will 
require  revaccination  to  maintain  their  immunity 
(Zarina et al., 2010; Orthopoulos et al., 2009).  Am. J. Immunol., 8 (2): 33-37, 2012 
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It is notable that some factors such as chronic kidney 
disease  and  haemodialysis  can  reduce  the  immune 
response to vaccines (Jahromi et al., 2009; 2011) and it 
has been not investigated between kidney function tests 
and immunity to pnemococcal vaccine in this research.  
 
CONCLUSION 
 
  Based on the results of this study, there is a need to 
re-address  the  approach  towards  revaccination  in  this 
immune-compromised  group  of  patients  by 
administering a booster pneumococcal vaccination in an 
attempt  to  recover  immunity  and  reduce  morbidity. 
Further researches with larger samples from other areas 
of IRAN are recommended for this approach.   
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